

Clinical Resource Tool



Click on the links below



Disease Frameworks & Clinical Guidance

NIA-AA Research Framework

<https://pubmed.ncbi.nlm.nih.gov/29653606/>

IWG-2 Criteria

<https://pubmed.ncbi.nlm.nih.gov/24849862/>

2023: Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's Association Workgroup

<https://aaic.alz.org/diagnostic-criteria.asp>

Alzheimer's Association: Guidelines Index

[https://www.alz.org/professionals/health-systems-medical-professionals/guidelines_index_\(1\)](https://www.alz.org/professionals/health-systems-medical-professionals/guidelines_index_(1))



Patient Resources



AARP

<https://www.aarp.org/caregiving/>



Alzheimer's Association

<https://www.alz.org/>



Family Caregiver Alliance

<https://www.caregiver.org/>



ALZConnected

<https://alzconnected.org/>



Additional Readings

Pathophysiology of Alzheimer's Disease

Yarns BC, et al. Psychiatr Clin North Am. 2022 Dec;45(4):663-676

2023 Alzheimer's Disease Facts and Figures

Alzheimer's Association. Alzheimers Dement 2023 Apr;19(4):1598-1695.

Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring

Oostveen WM, et al. Int J Mol Sci. 2021 Feb 20;22(4):2110.

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Haeberlein SB, et al. J Prev Alz Dis 2022;2(9):197-210.

Lecanemab in Early Alzheimer's Disease

van Dyck CH, et al. N Engl J Med. 2023 Jan 5;388(1):9-21.

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Sims JR, et al. N Engl J Med. 2023 Jan 5;388(1):9-21.